NCT02262793已完成1 期
Relative Bioavailability of Telmisartan in Micardis® and of Dipyridamole in Aggrenox® After Co-administration Compared to the Bioavailability of Telmisartan Respectively of Dipyridamole After Oral Administration of 80 mg Telmisartan Respectively of 25 mg ASA/200 mg Extended-release Dipyridamole Alone. An Open-label, Randomised, Single-dose, Four-way Crossover Study in 24 Healthy Female and Male Subjects
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 24
- 主要终点
- Cmax (maximum concentration in plasma)
研究概览
简要总结
To investigate the relative bioavailability of telmisartan respectively of dipyridamole after concomitant administration of 80 mg telmisartan in Micardis® and 25 mg acetylsalicylic acid (ASA)/200 mg extended release (ER) dipyridamole (DP) in Aggrenox® (Test 1) relative to ER-DP in Aggrenox® alone (Reference 1), respectively relative to telmisartan in Micardis® alone (Reference 2).
To investigate the relative bioavailability of dipyridamole respectively of telmisartan administered as 25 mg ASA/200 mg ER-DP 30 minutes after intake of 80 mg telmisartan (Test 2) relative to dipyridamole in Aggrenox® alone (Reference 1), respectively relative to telmisartan in Micardis® alone (Reference 2).
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 21 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Healthy females and males according to the following criteria:
- •Based upon a complete medical history, including the physical examination, vital signs (BP, HR), 12-lead ECG, clinical laboratory tests
- •No finding deviating from normal and of clinical relevance
- •No evidence of a clinically relevant concomitant disease
- •Age ≥21 and Age ≤65 years
- •BMI ≥18.5 and BMI ≤29.9 kg/m2 (Body Mass Index)
- •Signed and dated written informed consent prior to admission to the study in accordance with Good Clinical Practice (GCP) and the local legislation
排除标准
- •Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders
- •Surgery of gastrointestinal tract (except appendectomy)
- •Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or neurological disorders
- •History of relevant orthostatic hypotension, fainting spells or blackouts.
- •Chronic or relevant acute infections
- •History of allergy/hypersensitivity (including drug allergy) which is deemed relevant to the trial as judged by the investigator
- •Intake of drugs with a long half-life (>24 hours) within at least one month or less than 10 half-lives of the respective drug prior to administration or during the trial
- •Use of drugs which might reasonably influence the results of the trial based on the knowledge at the time of protocol preparation within 10 days prior to administration or during the trial
- •Participation in another trial with an investigational drug within two months prior to administration or during the trial
- •Smoker (more than 10 cigarettes/day or 3 cigars/day or 3 pipes/day)
- •Inability to refrain from smoking on trial days
- •Alcohol abuse (more than 60 g/day)
- •Blood donation (more than 100 mL within four weeks prior to administration or during the trial)
- •Excessive physical activities (within one week prior to administration or during the trial)
- •Any laboratory value outside the reference range that is of clinical relevance
- •Inability to comply with dietary regimen of study centre
- •History of hereditary fructose intolerance
- •History of any familial bleeding disorder
- •Veins unsuited for i.v. puncture on either arm (e.g. veins which are difficult to locate, access or puncture, veins with a tendency to rupture during or after puncture, etc.)
- •Inability to comply with the investigators instructions
- •For female subjects:
- •Positive pregnancy test
- •No adequate contraception e.g. oral contraceptives, sterilization, intrauterine device (IUD)
- •Inability to maintain this adequate contraception during the whole study period
- •Lactation period
研究组 & 干预措施
telmisartan and ASA/ER-DP (concomitant)
Experimental
干预措施: ASA/ER-DP (Drug)
telmisartan and ASA/ER-DP (concomitant)
Experimental
干预措施: telmisartan (Drug)
ASA/ER-DP alone
Active Comparator
干预措施: ASA/ER-DP (Drug)
telmisartan and ASA/ER-DP (consecutively)
Experimental
干预措施: telmisartan (Drug)
telmisartan and ASA/ER-DP (consecutively)
Experimental
干预措施: ASA/ER-DP (Drug)
telmisartan
Active Comparator
干预措施: telmisartan (Drug)
结局指标
主要结局
Cmax (maximum concentration in plasma)
时间窗: up to 72 hours following drug administration
AUC0-∞ (area under the concentration time curve in plasma from 0 extrapolated to infinity)
时间窗: up to 72 hours following drug administration
次要结局
- AUC0-tz (area under the concentration-time curve in plasma over the time interval from 0 to the time of the last quantifiable data point)(up to 72 hours following drug administration)
- λz (terminal rate constant in plasma)(up to 72 hours following drug administration)
- t1/2 (terminal half-life of the analytes in plasma)(up to 72 hours following drug administration)
- MRTpo (mean residence time of the analyte in the body after p.o. administration)(up to 72 hours following drug administration)
- Number of subjects with clinically significant findings in vital signs(up to 8 days after last drug administration)
- AUCt1-t2 (Area under the concentration time curve in plasma over the time interval t1 to t2)(up to 72 hours following drug administration)
- Number of subjects with clinically significant findings in 12 lead ECG(up to 8 days after last drug administration)
- tmax (time from dosing to the maximum concentration of the analytes in plasma)(up to 72 hours following drug administration)
- CL/F (apparent clearance of the analytes in the plasma after extravascular administration)(up to 72 hours following drug administration)
- Vz/F (apparent volume of distribution during the terminal phase λz following an extravascular dose)(up to 72 hours following drug administration)
- Number of subjects with adverse events(up to 8 days after last drug administration)
- Number of subjects with clinically significant findings in laboratory tests(up to 8 days after last drug administration)
- Assessment of tolerability by the investigator on a 4-point scale(up to 8 days after last drug administration)
研究者
相似试验
已完成
1 期
Relative Bioavailability of Telmisartan and SR26334 After Co-administration Compared to the Bioavailability of Telmisartan and SR26334 After Administration of Telmisartan and Clopidogrel Alone in Healthy Male and Female SubjectsHealthyNCT02262650Boehringer Ingelheim24
已完成
1 期
Relative Bioavailability of Telmisartan/Amlodipine Fixed-dose Combination Compared to Its Mono-components in Healthy Male VolunteersHealthyNCT02259803Boehringer Ingelheim30
已完成
1 期
Bioavailability of Telmisartan/Amlodipine Fixed-dose Combination Compared to Its Mono-components in Healthy Male VolunteersHealthyNCT02259790Boehringer Ingelheim30
已完成
1 期
Bioavailability of Lacidipine and Telmisartan Fixed Dose Combination Tablets Relative to Separate Tablets in Healthy SubjectsHealthyNCT02209649Boehringer Ingelheim12
已完成
1 期
Relative Bioavailability of Telmisartan and HCTZ in Two Experimental Formulations Compared to the Standard Formulation Telmisartan and HCTZ in Healthy Female and Male SubjectsHealthyNCT02262572Boehringer Ingelheim24